Betagan
| Betagan | |
|---|---|
| DOSAGE | 1-2 gtts QD or BID |
| GENERIC | Levobunolol HCI ophthalmic solution, USP 0.25%, 0.5% |
| SIZE | 5mL, 10mL, 15mL |
| INDICATIONS | Reduces intraocular pressure (IOP) |
| MECHANISM OF ACTION | Non-selective beta adrenergic receptor blocker |
| MICROBIOLOGY | The predominant mechanism of ocular hypotensive action of topical beta-adrenergic blocking agents is likely due to a reduction in aqueous humor production |
| CONTRAINDICATIONS & WARNINGS | Patients with bronchial asthma, or with a history of bronchial asthma, or severe chronic obstructive pulmonary disease, sinus bradycardia; second and third degree atrioventricular block; overt cardiac failure, cardiogenic shock; or hypersensitivity to any component of these products. |
| PEDIATRIC USE | Safety and effectiveness in pediatric patients have not been established. |
| PREGNANCY | Pregnancy category C | There are no adequate and well-controlled studies in pregnant women. BETAGAN® ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus |
| NOTE | |